Lung Trials

Trial Title Who can participate? Where is the trial open? What question is the trial asking? Full trial information
CTRIAL 18-33 SOURCE Lung: Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours

This study is investigating the safety of delivering SABR treatment to ultracentral lung tumours. An ultracentral lung tumour is a tumour that is positioned near the windpipe, heart or the major blood vessels near the heart. These tumours are more challenging for us to treat because they are near such important organs which we want to protect. The SOURCE study is investigating the safety of treating these tumours with high-dose precise radiotherapy called Stereotactic Ablative Radiation Therapy. (SABR)

Patients with early stage non-small cell lung cancer (NSCLC) or with a single oligometastatic lesion in the lung which cannot be treated with surgey and are suitable to receive high dose radiation therapy known as SABR. To be suitable for the study the patient must have a lesion which is located centrally within the lungs, near to the windpipe, heart Or the major blood vessels near the heart.

Currently open in:

  • St. Luke’s Hospital Rathgar.
  • St. Luke’s Centre at St. James’s Hospital.
  • The Beacon Hospital

Planned to open in:

  • Belfast.

The study is evaluating the safety of delivering SABR (high dose radiation therapy) to people with a centrally located lung lesion. The treatment will be delivered over 8 hospital visits and safety will be measured as part of the routine follow-up for these patients. Patients will have CT scans as part of their routine follow-up. They will have an additional PET scan 6 months after their treatment is finished and a lung function test 12 months after their treatment is finished.
Trial information: